Myocardial Ischemia Related to Common Cancer Therapy-Prevention Insights.
Minerva Codruţa BădescuOana Viola BadulescuDragos Viorel ScripcariuLăcrămioara Ionela ButnariuIris Bararu-BojanDiana PopescuManuela CiocoiuEusebiu Vlad GorduzaIrina Iuliana CostacheElena RezusCiprian RezusPublished in: Life (Basel, Switzerland) (2022)
Modern antineoplastic therapy improves survival and quality of life in cancer patients, but its indisputable benefits are accompanied by multiple and major side effects, such as cardiovascular ones. Endothelial dysfunction, arterial spasm, intravascular thrombosis, and accelerated atherosclerosis affect the coronary arteries, leading to acute and chronic coronary syndromes that negatively interfere with the oncologic treatment. The cardiac toxicity of antineoplastic agents may be mitigated by using adequate prophylactic measures. In the absence of dedicated guidelines, our work provides the most comprehensive, systematized, structured, and up-to-date analyses of the available literature focusing on measures aiming to protect the coronary arteries from the toxicity of cancer therapy. Our work facilitates the implementation of these measures in daily practice. The ultimate goal is to offer clinicians the necessary data for a personalized therapeutic approach for cancer patients receiving evidence-based oncology treatments with potential cardiovascular toxicity.
Keyphrases
- cancer therapy
- coronary artery
- coronary artery disease
- drug delivery
- oxidative stress
- primary care
- healthcare
- palliative care
- left ventricular
- systematic review
- cardiovascular disease
- liver failure
- drug induced
- aortic stenosis
- pulmonary embolism
- quality improvement
- electronic health record
- physical activity
- squamous cell
- big data
- rectal cancer
- intensive care unit
- blood flow
- clinical practice
- mesenchymal stem cells
- climate change
- combination therapy
- deep learning
- free survival
- atrial fibrillation
- lymph node metastasis
- childhood cancer